HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
Otto Metzger(Dana-Farber Cancer Institute), Ian E. Krop(Yale Cancer Center), Denise A. Yardley(Sarah Cannon), Aditya Bardia(UCLA Health), Eileen Wrabel(Dana-Farber Cancer Institute), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Michalina Janiszewska(Scripps Research Institute), Ingrid A. Mayer(Vanderbilt University), Eric P. Winer(University of Vermont), Lorenzo Trippa(Harvard University), Vandana G. Abramson(Vanderbilt University), Tari A. King(Brigham and Women's Hospital), Giuseppe Viale(University of Milan), Adrienne G. Waks(Harvard University), Tianyu Li(Dana-Farber Cancer Institute), Kornélia Polyák(Dana-Farber Cancer Institute), Michelle K. DeMeo(Dana-Farber Cancer Institute), Laura M. Spring(Massachusetts General Hospital)
Cited by 82
Related Papers
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
|Nature reviews. Cancer|2009|3.3k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
A model for p53-induced apoptosis
|Nature|1997|2.5k